0001085277
2015-01-01
2015-03-31
0001085277
2015-03-31
0001085277
2014-12-31
0001085277
SKVI:ConvertibleNote1Member
2014-01-01
2014-12-31
0001085277
SKVI:ConvertibleNote2Member
2014-01-01
2014-12-31
0001085277
us-gaap:ConvertibleNotesPayableMember
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable1Member
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable2Member
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable3Member
2015-03-31
0001085277
2014-01-01
2014-03-31
0001085277
SKVI:ConvertibleNotesPayable4Member
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable5Member
2015-03-31
0001085277
SKVI:ConvertibleNote1Member
2014-12-31
0001085277
SKVI:ConvertibleNote2Member
2014-12-31
0001085277
SKVI:TwentyFourNotesPayableMember
2014-01-01
2014-12-31
0001085277
SKVI:TwentyFourNotesPayableMember
2013-05-01
2013-05-30
0001085277
SKVI:TwentyFourNotesPayableMember
2013-05-22
0001085277
SKVI:FourteenNotesPayableMember
2014-05-01
2014-05-30
0001085277
SKVI:FourteenNotesPayableMember
2014-05-20
0001085277
SKVI:FourteenNotesPayableMember
2014-08-19
2014-12-31
0001085277
us-gaap:ConvertibleNotesPayableMember
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable1Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable2Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable3Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable4Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable5Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable6Member
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable6Member
2015-01-01
2015-03-31
0001085277
SKVI:StockOptionsGranted1Member
2015-01-01
2015-03-31
0001085277
SKVI:Issuance1Member
2015-01-01
2015-03-31
0001085277
SKVI:Issuance2Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable8Member
2015-01-01
2015-03-31
0001085277
SKVI:ConvertibleNotesPayable8Member
2015-03-31
0001085277
2013-12-31
0001085277
SKVI:Issuance1Member
2015-03-31
0001085277
SKVI:Issuance2Member
2015-03-31
0001085277
2014-01-01
2014-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SKINVISIBLE INC
0001085277
10-Q
2015-03-31
false
--12-31
No
No
Yes
Smaller Reporting Company
Q1
2015
.001
.001
.001
.001
200000000
200000000
113813969
111813969
324670
324275
301897
288203
20068
26822
111110
1123078
209809
182083
70768
94909
118126
40466
57439
1998-03-06
48163
48163
113635
113635
39722
39722
12569
12569
113461
113461
327550
327550
395
336
13874
8510
28476
28476
111110
111110
20068
26822
11306
10367
24084
5717
-4763395
-4350671
73375
10038
4953
2321
68422
7717
352225
173111
366494
181957
-298072
-174240
-26
-125
-205639
-171009
-0.00
-0.00
111399613
110415949
21596
196602
513420
1071593
1071593
-292425
-333483
321032
321032
-96635
-103886
182083
182083
-100302
-109277
106152
106152
-46003
-49491
142501
142501
-71259
-75937
1
1
1
1
1
1
1
1
5698
9457
1145
1145
154785
290359
2880
3275
344272
352420
501937
646054
492333
420762
399295
348111
1910
1910
980000
1119518
1112764
1252276
1173178
4245332
3056725
5265332
4996725
113814
111814
21467643
21378656
-26344852
-25841141
501937
646054
1800
1000000
795065
874163
-205665
-169334
126346
83155
59507
51756
32323
16641
118126
118126
-100400
-106223
2013-05-22
2014-05-19
1000000
1000000
0.1
0.09
0.09
0.09
1000000
1000000
P2Y
P2Y
10288
41058
10251
8975
3488
4678
5823
1994
2831
182083
106153
142501
118126
52476
1000000
40558
65295
50000
30000
.04
0.04
0.03
0.03
0.03
.025
0.04
.04
0.06
0.06
0.04
0.04
.04
.03
.05
.05
.07
.07
0.10
2010-01-12
2016-10-01
40558
40558
-36433
-38427
1250000
750000
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
.10
.10
.10
.10
.10
.10
.10
.10
P3Y
P3Y
P3Y
P3Y
P3Y
P3Y
P3Y
P3Y
51485
3990
646169
14750
14758
200000
.05
0.07
200000
.05
P5Y
8800
8800
2015-03-31
2015-01-26
2015-01-27
80000
65295
65295
-54607
-57438
-503711
-345249
14269
8846
88039
80742
-43191
-13126
3759
6113
71571
55063
51184
26499
-309280
-179312
-5726
-12448
-5726
-12448
60000
5000
140000
-4922
-175006
-196682
66441
47422
5400
113813969
1020000
1940000
8800
54450
78
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Description of business</u> – Skinvisible,
Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical,
transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process
for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications
within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological
formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains
executive and sales offices in Las Vegas, Nevada.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>History </u>– Skinvisible, Inc. (referred
to as the “Company”) was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company
underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s
name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 9, 2014, the Company formed Kinatri
USA Inc., a new wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our
patented Invisicare® technology. As part of our strategic focus on revenue generation and creating shareholder value, Kintari
USA Inc. products will be sold via network marketing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Kintari product portfolio consists of anti-aging
products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific
evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent
ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which we believe
cannot be duplicated. Additional products will be added to enhance this product line as the company grows and expands.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Skinvisible, Inc. together with its subsidiary
shall herein be collectively referred to as the “Company”.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Going concern</u> – The accompanying
financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. The Company has incurred cumulative net losses of $26,344,852 since its inception
and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise
additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful
development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable
operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial
doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do
not include any adjustments that may result from the outcome of these aforementioned uncertainties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Principles of consolidation</u> –
The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances
and transactions have been eliminated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of estimates</u> – The preparation
of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash and cash equivalents - </u>The purposes
of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original
maturities of three months or less to be cash equivalents. There are $21,596 and $196,602 in cash and cash equivalents as of March
31, 2015 and December 31, 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reflected in the balance
sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these
items.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by the Fair Value Measurements
and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2)
inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable
inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three levels of the fair value hierarchy
are described below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1: Unadjusted quoted prices
in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2: Quoted prices in markets
that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset
or liability;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3: Prices or valuation techniques
that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market
activity).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue recognition</u></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><u>Product sales</u> – Revenues
from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer
and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to
receive reasonably assured payments for products sold and delivered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><u>Royalty sales</u> – The
Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies
or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><u>Distribution and license rights
sales</u> – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized
over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned
the right to receive and retain reasonably assured payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><u>Costs of Revenue</u> – Cost
of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion
of the cost of revenue.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts Receivable</u> – Accounts
receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days
from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines
that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected
is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment
of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2015, the Company
had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by
the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription
product, ProCort®.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Inventory </u>– Substantially all
inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination
of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Goodwill and intangible assets</u> –
The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “<i>Intangibles
– Goodwill and Other</i>”. According to this statement, goodwill and intangible assets with indefinite lives are no
longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for
goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying
value of assets are calculated at the lowest level for which there are identifiable cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income taxes</u> – The Company accounts
for its income taxes in accordance with FASB Codification Topic ASC 740-10, “<i>Income Taxes</i>”, which requires recognition
of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates
is recognized in income in the period that includes the enactment date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-based compensation</u> – The
Company follows the guidelines in FASB Codification Topic ASC 718-10 “<i>Compensation-Stock Compensation</i>”, which
requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors
including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated
fair values.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock based compensation expense recognized
under ASC 718-10 for the year ended March 31, 2015 and December 31, 2014 totaled $8,800 and $54,450, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings (loss) per share</u> – The
Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “<i>Earnings Per Share</i>”,
Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average
number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been
presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents)
would have an anti-dilutive effect.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following as of
March 31, 2015 and December 31, 2014:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2015</td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify">Machinery and equipment</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">48,163</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">48,163</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Furniture and fixtures</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">113,635</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">113,635</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify">Computers, equipment and software</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">39,722</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">39,722</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Leasehold improvements</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">12,569</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">12,569</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify">Lab equipment</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">113,461</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">113,461</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify"> Total</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">327,550</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">327,550</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify">Less: accumulated depreciation</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(324,670</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(324,275</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify">Fixed assets, net of accumulated depreciation</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">2,880</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">3,275</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the three months ended
March 31, 2015 and 2014 was $395 and $336, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consist of the following as of March
31, 2015 and December 31, 2014</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2015</td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify">Shipping and Packing materials</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">14,750</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">14,758</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Marketing Supplies</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">19,766</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify">Finished Goods</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">59,507</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left">$</td>
<td style="text-align: right">51,756</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify">Raw Materials</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">32,323</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">16,641</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify"> Total</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">126,346</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">83,155</td>
<td style="text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents and trademarks are capitalized at their
historical cost and are amortized over their estimated useful lives. As of March 31, 2015, patents and trademarks total $646,169,
net of $301,897 of accumulated amortization. Amortization expense for the three months ended March 31, 2015 and 2014 was $13,874
and $8,510 respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License and distributor rights (“agreement”)
were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The
Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license
and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of March 31,
2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of option activity
during the three months ended March 31, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.75pt">Balance, December 31, 2014</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">9,750,000</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left">$</td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">0.05</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Options granted and assumed</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">200,000</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">0.05</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 9pt">Options expired</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Options canceled</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 9pt">Options exercised</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify; padding-left: 0.75pt">Balance, March 31, 2015</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left"> </td>
<td style="border-bottom: black 2.5pt double; text-align: right">9,950,000</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">0.05</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2015, 9,950,000 stock options
are exercisable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2015, the Company granted stock
options for 200,000 shares of its common stock with a strike price of $0.05. The stock options were exercisable upon grant
and have a life of 5 years. The stock options were valued at $8,800 using the Black-Scholes option pricing model based upon the
following assumptions: term of 5 years,  risk free interest rate of 1.37%, a dividend yield of 0% and volatility rates
of 483%.   The Company recorded an expense of $8,800 for the three months ended March 31, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock warrants -</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of warrants activity
during the three months ended March 31, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.75pt">Balance, December 31, 2014</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">2,541,030</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left">$</td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">0.05</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Warrants granted and assumed</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">1,000,000</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">0.07</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 9pt">Warrants expired</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Warrants canceled</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 9pt">Warrants exercised</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify; padding-left: 0.75pt">Balance, March 31, 2015</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left"> </td>
<td style="border-bottom: black 2.5pt double; text-align: right">3,541,030</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">0.06</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All warrants outstanding as of March 31, 2015
are exercisable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 22, 2013 the Company approved a financing
plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the year ended December 31, 2013 the Company
entered into twenty-four 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from
the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products:
US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 19, 2014 the Company approved a financing
plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. For the period from May 19, 2014
to March 31, 2015 the Company entered into twenty-seven 9% notes payable to investors and received total proceeds of $1,000,000.
The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the
Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2014 $980,000 of the Notes
were due in less than 12 months and have been classified as Current notes payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended 2013 various officers
advanced funds to support the daily operations of the company. As of March 31, 2015, $1,145 remained due to related parties as
repayment for advanced monies, all related other party notes have been extinguished or re-negotiated as convertible notes. See
note 10.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 55%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: justify">Convertible Notes Payable at consists of the following:</td>
<td> </td>
<td colspan="3" style="text-align: center">March 31,</td>
<td> </td>
<td colspan="3" style="text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand.  The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. The Note is currently in default, no penalties occur due to default.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">28,476</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">28,476</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 5.4pt">$1,000,000 face value 9% unsecured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,288 during the three months ended March 31, 2015. The original issue discount feature is valued under the intrinsic value method. <br />  <br />On March 3, 2015 the Company executed an extension agreement with a note holder who's note had reached maturity. The note was extended for an additional 12 months and is now due in December of 2015. <br />  <br />On March 11, 2015 the Company executed an extension agreement with a note holder who's note had reached maturity. The note was extended for an additional 24 months and is now due in October of 2016.</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 0.5in">Original issue discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">111,110</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">111,110</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(20,068</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(26,822</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,119,518</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,112,764</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 55%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="text-align: justify">Convertible Notes Payable Related Party at consists of the following:</td>
<td> </td>
<td colspan="3" style="text-align: center">March 31,</td>
<td> </td>
<td colspan="3" style="text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 5.4pt">On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $41,058 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">1,071,593</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">1,071,593</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(292,425</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(333,483</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,251 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">321,032</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">321,032</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">(93,635</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">(103,886</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $8,975 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">182,083</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">182,083</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(100,302</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(109,277</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $3,488 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">106,152</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">106,152</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(46,003</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(49,491</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $4,678 during the three months ending March 31, 2015. The beneficial conversion feature is valued under the intrinsic value method.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">142,501</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">142,501</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(71,259</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(75,937</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $5,823 during the three months ending March 31, 2015.   The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">118,126</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">118,126</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(100,400</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(106,223</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,994 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">40,558</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">40,558</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(36,433</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(38,427</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On December 31, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $65,295 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $65,295 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $57,439. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $2,831 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">65,295</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">65,295</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(54,607</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(57,438</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,252,276</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,173.178</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue 200,000,000
shares of $0.001 par value common stock. The Company had 113,813,969 and 111,813,969 issued and outstanding shares of common stock
as of March 31, 2015 and December 31, 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2015 the Company received $50,000
pursuant to a private placement agreement with an investor to purchase 1,250,000 shares of Skinvisible Inc. $0.001 par value common
stock and 625,000 warrants. The warrants allow the holder to purchase shares of the Company's common stock at $0.07 on or before
January 21, 2016.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 27, 2015 the Company received $30,000
pursuant to a private placement agreement with an investor to purchase 750,000 shares of Skinvisible Inc. $0.001 par value common
stock and 375,000 warrants. The warrants allow the holder to purchase shares of the Company's common stock at $0.07 on or before
January 21, 2016.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Lease obligations</u> – The Company
has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of March 31,
2015, are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 24,084</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2016 5,717</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events subsequent
to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined
that there are no such events that would require adjustment to, or disclosure in, the financial statements.</p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Skinvisible, Inc., (referred to as the “Company”)
is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery
system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic
polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter,
personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for
a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices
in Las Vegas, Nevada.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Skinvisible, Inc. (referred to as the “Company”)
was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on
February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc.
was also changed to Skinvisible Pharmaceuticals, Inc.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 9, 2014, the Company formed Kinatri
USA Inc., a new wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our
patented Invisicare® technology. As part of our strategic focus on revenue generation and creating shareholder value, Kintari
USA Inc. products will be sold via network marketing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Kintari product portfolio consists of anti-aging
products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific
evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent
ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which we believe
cannot be duplicated. Additional products will be added to enhance this product line as the company grows and expands.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Skinvisible, Inc. together with its subsidiary
shall herein be collectively referred to as the “Company”.</p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have
been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the
normal course of business. The Company has incurred cumulative net losses of $26,344,852 since its inception and requires capital
for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital
through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of
the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations
are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt
about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not
include any adjustments that may result from the outcome of these aforementioned uncertainties.</font></p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The consolidated financial statements include
the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.</font></p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the United States requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.
Actual results could differ from those estimates.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For purposes of the statement of cash flows, the Company considers all highly
liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. There
are $21,596 and $196,602 in cash and cash equivalents as of March 31, 2015 and December 31, 2014, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reflected in the balance
sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these
items.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by the Fair Value Measurements
and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2)
inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable
inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three levels of the fair value hierarchy
are described below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1: Unadjusted quoted prices
in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2: Quoted prices in markets
that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset
or liability;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3: Prices or valuation techniques
that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market
activity).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Product sales</u> – Revenues
from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer
and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to
receive reasonably assured payments for products sold and delivered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Royalty sales</u> – The
Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies
or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Distribution and license rights
sales</u> – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized
over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned
the right to receive and retain reasonably assured payments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Costs of Revenue</u> – Cost
of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion
of the cost of revenue.</p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable is comprised of uncollateralized
customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount
of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance
that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each
accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates
the portion, if any, of the balance that will not be collected. As of March 31, 2015, the Company had not recorded a reserve for
doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license
agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Substantially all inventory consists of finished goods and are valued based
upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory
requires a write-down is based on an evaluation of inventory.</p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company follows Financial Accounting
Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “<i>Intangibles – Goodwill and
Other</i>”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization,
but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted
cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated
at the lowest level for which there are identifiable cash flows.</font></p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for its income taxes
in accordance with FASB Codification Topic ASC 740-10, “<i>Income Taxes</i>”, which requires recognition of deferred
tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts
of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the guidelines in FASB
Codification Topic ASC 718-10 “<i>Compensation-Stock Compensation</i>”, which requires the measurement and recognition
of compensation expense for all share-based payment awards made to employees and directors including employee stock options and
employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock based compensation expense recognized
under ASC 718-10 for the year ended March 31, 2015 and December 31, 2014 totaled $8,800 and $54,450, respectively.</p>
<p style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company reports earnings (loss) per
share in accordance with FASB Codification Topic ASC 260-10 “<i>Earnings Per Share</i>”, Basic earnings (loss) per
share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.
Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of
the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive
effect.</font></p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2015</td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify">Machinery and equipment</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">48,163</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">48,163</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Furniture and fixtures</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">113,635</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">113,635</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify">Computers, equipment and software</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">39,722</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">39,722</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Leasehold improvements</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">12,569</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">12,569</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify">Lab equipment</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">113,461</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">113,461</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify"> Total</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">327,550</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">327,550</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify">Less: accumulated depreciation</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(324,670</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(324,275</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify">Fixed assets, net of accumulated depreciation</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">2,880</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">3,275</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2015</td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify">Shipping and Packing materials</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">14,750</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">14,758</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify">Marketing Supplies</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">19,766</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify">Finished Goods</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">59,507</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left">$</td>
<td style="text-align: right">51,756</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify">Raw Materials</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">32,323</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">16,641</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify"> Total</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">126,346</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">83,155</td>
<td style="text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.75pt">Balance, December 31, 2014</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">9,750,000</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left">$</td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">0.05</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Options granted and assumed</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">200,000</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">0.05</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 9pt">Options expired</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Options canceled</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 9pt">Options exercised</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify; padding-left: 0.75pt">Balance, March 31, 2015</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left"> </td>
<td style="border-bottom: black 2.5pt double; text-align: right">9,950,000</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">0.05</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td>
<td> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.75pt">Balance, December 31, 2014</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">2,541,030</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left">$</td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">0.05</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Warrants granted and assumed</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">1,000,000</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">0.07</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 9pt">Warrants expired</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 9pt">Warrants canceled</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">—  </td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 9pt">Warrants exercised</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">—  </td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 2.5pt; text-align: justify; padding-left: 0.75pt">Balance, March 31, 2015</td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left"> </td>
<td style="border-bottom: black 2.5pt double; text-align: right">3,541,030</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">0.06</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<table cellspacing="0" cellpadding="0" align="center" style="width: 55%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
<td style="text-align: justify">Convertible Notes Payable at consists of the following:</td>
<td> </td>
<td colspan="3" style="text-align: center">March 31,</td>
<td> </td>
<td colspan="3" style="text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand.  The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. The Note is currently in default, no penalties occur due to default.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">28,476</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 20%; text-align: right">28,476</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 5.4pt">$1,000,000 face value 9% unsecured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,288 during the three months ended March 31, 2015. The original issue discount feature is valued under the intrinsic value method. <br />  <br />On March 3, 2015 the Company executed an extension agreement with a note holder who's note had reached maturity. The note was extended for an additional 12 months and is now due in December of 2015. <br />  <br />On March 11, 2015 the Company executed an extension agreement with a note holder who's note had reached maturity. The note was extended for an additional 24 months and is now due in October of 2016.</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td>
<td style="padding-bottom: 1pt; text-align: left"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td>
<td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 0.5in">Original issue discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">111,110</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">111,110</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(20,068</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(26,822</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,119,518</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,112,764</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<table cellspacing="0" cellpadding="0" align="center" style="width: 55%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="text-align: justify">Convertible Notes Payable Related Party at consists of the following:</td>
<td> </td>
<td colspan="3" style="text-align: center">March 31,</td>
<td> </td>
<td colspan="3" style="text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 5.4pt">On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $41,058 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">1,071,593</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">1,071,593</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(292,425</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(333,483</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,251 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">321,032</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">321,032</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="width: 54%; padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">(93,635</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td>
<td style="width: 1%; padding-bottom: 1pt"> </td>
<td style="width: 1%; border-bottom: black 1pt solid; text-align: left"> </td>
<td style="width: 20%; border-bottom: black 1pt solid; text-align: right">(103,886</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $8,975 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">182,083</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">182,083</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(100,302</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(109,277</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $3,488 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">106,152</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">106,152</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(46,003</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(49,491</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $4,678 during the three months ending March 31, 2015. The beneficial conversion feature is valued under the intrinsic value method.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">142,501</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">142,501</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-bottom: 1pt; text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(71,259</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid; text-align: left"> </td>
<td style="border-bottom: black 1pt solid; text-align: right">(75,937</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $5,823 during the three months ending March 31, 2015.   The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">118,126</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">118,126</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(100,400</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(106,223</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="width: 54%; text-align: justify; padding-left: 5.4pt">On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,994 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">40,558</td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td>
<td style="width: 20%; text-align: right">40,558</td>
<td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(36,433</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(38,427</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="text-align: justify; padding-left: 5.4pt">On December 31, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $65,295 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $65,295 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $57,439. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $2,831 during the three months ending March 31, 2015.  The beneficial conversion feature is valued under the intrinsic value method.</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">65,295</td>
<td style="text-align: left"> </td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">65,295</td>
<td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; padding-left: 0.5in">Unamortized debt discount</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(54,607</td>
<td style="text-align: left">)</td>
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: right">(57,438</td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,252,276</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right">1,173.178</td>
<td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
19766
9950000
9750000
.05
0.05
3541030
2541030
0.06
1000000
9950000
1000000
1000000
375000
375000